5/22/2018 The Big Picture At Unilife - Unilife Corporation (NASDAQ:UNIS) | Seeking Alpha


https://seekingalpha.com/article/1886091-the-big-picture-at-unilife 1/23


The Big Picture At Unilife
Dec. 9, 2013 11:28 AM ET18 comments
by: Richard Pearson


Investment considerations


As bulls and bears debate their longer term expectations for revenues at Unilife
(NASDAQ:UNIS), many have missed the fact that there are near-term catalysts which can
be expected to have a very certain impact on the share price well before these longer term
forecasts have a chance to play out.


Investors should also pay close attention to the stock promotion efforts which have
accompanied the recent press releases and they should be aware of some nearly identical
promotions in the past. As shown below, these types of stock promotions can often create
more bounce in the share price than the actual news released by the company itself.


Separately, investors who wish to assess the longer term revenue prospects should make
themselves aware of the current competitive environment. Many investors appear to have
missed the existence of numerous competitors with similar product offerings who already
have substantial cooperation from big pharma players.


As a final consideration, many investors have engaged in substantial debate over two
negative articles which were published in Forbes in September. These articles contributed
to significant volatility in the share price when they discussed a whistle blower lawsuit
brought against Unilife by a former employee. Many investors appear to have never read
the actual lawsuit and instead have simply relied upon the interpretation as represented by
Forbes. Anyone with a longer term interest in Unilife should certainly read the suit
themselves and come to their own interpretation. I have included as an Appendix a link to
the full lawsuit text filing along with several text excerpts.


Section 1: Long term theses vs. near term catalysts


Last week was a volatile one for shareholders in Unilife.


On Monday, the shares had traded as low as $4.03, closing at $4.15. But after the market
closed, Unilife announced "an agreement with Novartis to supply clinical products from
one of its platforms of injectable drug delivery systems for use with one of Novartis'
targeted early-stage pipeline drugs."



https://seekingalpha.com/symbol/UNIS

http://finance.yahoo.com/news/unilife-announces-clinical-supply-agreement-223000378.html
5/22/2018 The Big Picture At Unilife - Unilife Corporation (NASDAQ:UNIS) | Seeking Alpha


https://seekingalpha.com/article/1886091-the-big-picture-at-unilife 2/23


The mere mention of "an agreement with Novartis" had a predictable effect on the share
price, and Unilife quickly traded as high as $5.25 in extended hours trading - an immediate
gain of more than 25%.


These gains followed similar gains the previous week, following the announcement of a
long-term supply agreement with Hikma Pharmaceuticals on November 20th. Just prior to
this announcement, the stock had closed at $2.80.


After trading to as high as $5.25 in extended hours, the shares ended the week at $4.31,
but had traded as low as $4.16 again on Friday. In other words, by the end of the week,
Unilife had already given up almost all of its sharp gains following the Novartis release.
The stock has already received price target upgrades from its three investment banks last
week, but this appears to have provided very little support for the share price.


An outpouring of ANALYSIS on Wednesday added to the volatility in the share price, but
appears to have not given much direction to the share price. In that one day, there were
three large short articles and two large long articles published. These authors took turns
repeating one another, contradicting one another and ignoring one another. All of this also
happened to occur on the same exact day that CEO Alan Shortall was presenting at a
conference in New York. Not surprisingly, the share price was very volatile that day, at
times being down by 10% or up by 5%. It was equally unsurprising that the share price
finally ended the volatile day almost entirely unchanged (up by just 2 cents).



http://finance.yahoo.com/news/unilife-signs-long-term-supply-140000733.html

https://seekingalpha.com/symbol/unis?source=search_general&s=unis

https://static.seekingalpha.com/uploads/2013/12/8/4238561-1386552177617008-Richard-Pearson_origin.jpg
5/22/2018 The Big Picture At Unilife - Unilife Corporation (NASDAQ:UNIS) | Seeking Alpha


https://seekingalpha.com/article/1886091-the-big-picture-at-unilife 3/23


The bull thesis is based on the opinion that this recent series of supply agreements will
ultimately produce perhaps hundreds of millions in revenue from big pharma partners.
However, even the bulls acknowledge that meaningful revenues are not expected to
materialize until after several ramp up periods of as long as four years.


The bear thesis was fully detailed by Kerrisdale Capital which notes that recent
announcements from Unilife are nearly identical to numerous announcements stretching
back 10 years, each of which suggested that the onset of massive revenues was
imminent. Such announcements had consistently caused the share price to soar
dramatically, just as they have again done in the past two weeks. As they have been
recently, analysts were then quick to upgrade the stock. Yet revenues for Unilife have
continued to dwindle while Unilife has steadily issued nearly 40 million new shares in just
the past few years.


For those looking to trade the stock, the inherent problem with both of these bull and bear
theses is that both are predicated on how potential contracts and revenues will play out
over a period of several years. Given the tremendous volatility in the stock recently, long-
term views may not be of ideal use.


Both sides are free to speculate on the longer term future of Unilife. However in the
near term, one thing is quite certain: By the end of December, Unilife will likely be
out of cash and the company is almost certain to issue a substantial amount of
equity before the Christmas holiday. This is the near-term catalyst.


Author Dr. Hugh Akston illustrated this catalyst quite clearly in a recent article. As of
September 30th (i.e. two months ago, its last reported quarter), Unilife was down to just $7
million in cash. The company steadily burns around $3 million every month. The company
did receive $5 million as an upfront payment from Sanofi in October, but Unilife has
already disclosed that it plans on paying down a loan to Varilease for roughly that amount.
As of right now, Unilife is therefore down to around $1 million in available cash vs. its
consistent cash burn of around $3 million per month.


The incentive to conduct a very large equity offering is clearly substantial. Last week
(following the sharp spike), Unilife had quickly risen by nearly 90% and was trading at its
highest levels since 2011. But this is simply on a "nominal" share price level. In reality, the
large number of shares which have been issued every year means that last week Unilife
was closing in on its highest ever valuation (market cap) since coming public in the US.



https://seekingalpha.com/article/1875491-unilife-history-of-missed-deadlines-aggressive-cash-burn-and-vague-supply-agreements-suggest-a-75-overvaluation

https://seekingalpha.com/article/1876361-unilife-a-look-at-the-novartis-news

http://www.secinfo.com/d14D5a.xDC7j.htm
5/22/2018 The Big Picture At Unilife - Unilife Corporation (NASDAQ:UNIS) | Seeking Alpha


https://seekingalpha.com/article/1886091-the-big-picture-at-unilife 4/23


Some investors may not realize this given that the share price has fallen from above
$10.00 to around $4.00 at present. Yet it remains the case that the market cap for Unilife
had just hit within around 10% of its highest ever valuation since trading in the US.


The recent upgrades by Unilife's investment banks were all based upon enthusiasm for
the Novartis announcement. Yet these banks are not privy to any additional information
beyond the press release, which we can all read equally well. The banks simply relied
upon this simple press release to provide generous upgrades to their share price targets.
Such jockeying for position ahead of a near-term equity financing suggests that these
banks are looking for an equity offering that will be bigger rather than smaller and which
will provide millions of dollars in investment banking fees to whoever is selected by Unilife.
Currying favor with the company by upgrading the stock should therefore have been fully
expected. These upgrades have failed to support the stock, so it appears that the market
has already come to this realization on its own.


Section 2: Evaluating the bull campaign


When looking at the "big picture" at Unilife, investors need to understand that there is an
active bull campaign which has been going on for quite some time. The details from this
particular effort are virtually identical to other campaigns, some of which I have highlighted
in past articles.


Here is how it typically works. (And readers should keep in mind that I am not specifically
referring to Unilife in this description. I am referring to a cookie cutter process that can be
seen very frequently across numerous micro cap reverse merger stock situations.)


In each case, the hyper enthusiasm involves a small, money losing reverse merger which
supposedly has the potential for massive near-term transformation along with billions in
revenue potential. At some point, the company issues one or more press releases which
happen to mention global mega giants within its industry. Specific terms which would allow
for proper revenue forecasting are typically not disclosed for competitive reasons or due to
"confidentiality". The share price often moves to some extent based on these press
releases. But much sharper gains appear when certain third party authors interpret these
press releases for us and then issue massive multi bagger share price forecasts. Share
prices can then often show additional gains of more than 50% in a very short period. But
the gains are typically very short lived. Over time most of these enthusiastic targets end
up giving up all of their gains, and in many cases they end falling even further for reasons
that will be shown below.
5/22/2018 The Big Picture At Unilife - Unilife Corporation (NASDAQ:UNIS) | Seeking Alpha


https://seekingalpha.com/article/1886091-the-big-picture-at-unilife 5/23


On Friday, author Tech Guru weighed in once again to help us "parse" the debate on
Unilife. He notes that he expects $50 million in revenue in 2014. By way of comparison,
over the past 5 years, Unilife has generated a cumulative total of only around $25 million
in revenues. But most of this came in 2010. More recently, revenues have dwindled to
around $0.6 million per quarter. During this time span of several years, Unilife has
repeatedly issued similar bullish forecasts which made statements such as:


"we have been swamped with demand from a lot of other pharma companies who also
have unmet needs."


"We expect to be supplying this to many pharma companies in the near future," Allan
said."


Past press releases dating back as far as 4 years include the following. (Note these are all
PRIOR TO 2013, and as such should have already had an impact on revenues).


2010 - Unilife and sanofi-aventis Agree to Exclusivity List for Unifill(TM) Ready-to-Fill
Syringe


2010 - Unilife and Stason Pharmaceuticals Sign Asian Distribution Agreement for the
Unitract(TM) 1mL Safety Syringe


2011 - Unilife Signs Clinical Development and Supply Agreement with Global
Pharmaceutical Company


2011 - Unilife Wins Supply Contract with Nation's Largest Healthcare Alliance


2011 - Unilife Starts Unifill Syringe Sales to Another Pharmaceutical Customer


2011 - Unilife Commences Initial Supply of the UnifillÂ® Syringe to Sanofi


2011 - Unilife on Schedule to Fill Initial Orders for Unifill Syringe


2012 - Unilife's Bolus Injector Platform Targeted by Global Pharmaceutical Company for
Use in Multi-Drug Program


2012 - Unilife Signs Long-Term Supply Contract for the Unifill Prefilled Syringe


In many cases, these press releases were just as exciting as the recent ones in 2013.
They also consistently provided (very brief) boosts to the share price of Unilife as
expected.


But the results have varied dramatically vs. expectations.



http://www.biopharma-reporter.com/Bio-Developments/Unilife-launches-Autoinfuser-range-publically

http://ir.unilife.com/releases.cfm?ReleasesType=&Year=

http://ir.unilife.com/releasedetail.cfm?ReleaseID=448725

https://seekingalpha.com/symbol/TM

http://ir.unilife.com/releasedetail.cfm?ReleaseID=450745

https://seekingalpha.com/symbol/TM

http://ir.unilife.com/releasedetail.cfm?ReleaseID=627779

http://ir.unilife.com/releasedetail.cfm?ReleaseID=611276

http://ir.unilife.com/releasedetail.cfm?ReleaseID=592618

http://ir.unilife.com/releasedetail.cfm?ReleaseID=590992

http://ir.unilife.com/releasedetail.cfm?ReleaseID=556954

http://ir.unilife.com/releasedetail.cfm?ReleaseID=719833

http://ir.unilife.com/releasedetail.cfm?ReleaseID=683876
5/22/2018 The Big Picture At Unilife - Unilife Corporation (NASDAQ:UNIS) | Seeking Alpha


https://seekingalpha.com/article/1886091-the-big-picture-at-unilife 6/23


The points from these graphs demonstrate the following: the share price has been steadily
declining for the past several years, even as Unilife has consistently issued millions of new
shares. Likewise, revenues have dwindled by more than 70% while losses have grown
substantially. All of this has occurred despite the consistent release of "news" from Unilife
which has been largely similar to that which was released in the past few weeks.


It is therefore unclear how Tech Guru could be so optimistic regarding a tremendous surge
in revenue next year.



https://static.seekingalpha.com/uploads/2013/12/8/4238561-13865523800121849-Richard-Pearson_origin.jpg

https://static.seekingalpha.com/uploads/2013/12/8/4238561-13865524242079394-Richard-Pearson_origin.jpg
5/22/2018 The Big Picture At Unilife - Unilife Corporation (NASDAQ:UNIS) | Seeking Alpha


https://seekingalpha.com/article/1886091-the-big-picture-at-unilife 7/23


A few months ago, I highlighted a different CAMPAIGN by Tech Guru with Neonode Inc.
(NASDAQ:NEON), which appears to be nearly identical to the efforts toward Unilife in
virtually all respects. The similarities and parallels here should be patently obvious to
anyone who has followed Unilife.


Tech Guru began writing on Neonode earlier in 2013. Between March and September, he
wrote bullish articles on the company on average every 2-3 weeks. Neonode is engaged
in licensing touch sensor technology, mostly to electronics OEMs.


Just like Unilife, money-losing microcap Neonode had put out several very promising
press releases this year which could be linked to global giants within its industry. Over a
period of months these included such heavy weights as Samsung and LG, along with
automotive contracts with Volvo. Clearly this was going to be huge and transformational.


Just like Unilife, Neonode had been putting out nearly identical press releases for years,
but consistently failed to generate meaningful revenues - despite the global giant partners.
Just like Unilife, Neonode has never earned a profit in its numerous years in business.
And just like Unilife, the press releases from Neonode were always kept vague and
omitted the most relevant details, typically due to competitive or confidentiality reasons.


Given that multiple years of nearly identical press releases from Neonode failed to
produce large scale revenues or any profits at all, it is unclear why Tech Guru would
project that more identical press releases in 2013 would somehow lead to near term
windfall profits and a skyrocketing share price. But by trumpeting names like LG and
Samsung and predicting returns of more than 400%, his articles did cause the share price
to briefly rise by around 60% to as high as $8.84 up from around $5.00 in March.


Just like with Unilife, the investment bankers were quick to upgrade Neonode based on
nothing more than the very vague press releases. Investment bank Craig Hallum initiated
coverage on Neonode when the stock price was just $3-4, and put a target of $7.50 on the
stock, implying that they expected Neonode to double. The timing of this coverage was
downright bizarre given that Neonode had just lost its largest customer, Amazon
(NASDAQ:AMZN), which had been responsible for 40% of its revenues at the time. But
the upgrade worked and Neonode rose. By August, Neonode had still failed to replace its
lost revenues and reported a notably large earnings miss which sent the stock plunging by
more than 20%. What did Craig Hallum do? They upgraded the stock again - now with a
$10.00 target. This upgrade, along with more bullish articles by Tech Guru (predicting a
$27 share price) sent the stock to just under $9.00. This sequence of events is all detailed
clearly in my September article.



https://seekingalpha.com/author/tech-guru/articles/symbol/neon

https://seekingalpha.com/symbol/NEON

http://www.neonode.com/newsroom/

https://seekingalpha.com/article/1686262-neonode-investors-feel-duped-shares-to-fall-further

https://seekingalpha.com/symbol/AMZN

https://seekingalpha.com/article/1686262-neonode-investors-feel-duped-shares-to-fall-further
5/22/2018 The Big Picture At Unilife - Unilife Corporation (NASDAQ:UNIS) | Seeking Alpha


https://seekingalpha.com/article/1886091-the-big-picture-at-unilife 8/23


By now, this sequence of events should all feel very familiar to those who follow Unilife. So
far they have been largely identical.


What happened next with Neonode was quite predictable. Neonode and its management
sold $19 million in equity. Craig Hallum ran the deal (as expected) and made millions in
fees. Meaningful revenues from the mega announcements may still be years away (if
ever) and the stock price quickly fell by around 30% back to around $5.00 - right where it
began. Prior to the offering, Tech Guru had been writing bullish articles on Neonode every
2-3 weeks for a 5 month period. This was a dedicated and persistent effort. But following
the offering, the articles suddenly ceased for several months.


Many investors may wonder if such promotions can actually have a meaningful impact on
the share price. The answer is a categorical "yes, they can." This point can be made clear
with a separate example.


Lately the Novartis news has taken center stage to the point where many investors have
stopped focusing on the recent Hikma news from November 20th. The Hikma
announcement caused Unilife to soar by more than 30% to $4.03. But after the initial
surge, investors began a meaningful sell-off as they fully evaluated the news. It was only a
double promotion from a service called "The Focused Stock Trader" that sent Unilife
soaring.


The graph below illustrates the sequence of events.


- Nov19 / 20 - Unilife announces Novartis news - stock rises to $4.03


- Nov21 - UNIS stock immediately trades down as low as $3.63 (down 9.9%) closes at
$3.73


- Nov22 - 25 - UNIS struggles to hold above $4.00


- Nov26 - TFST promo article to paid subscribers only - UNIS immediately jumps from
$3.85 to as high as $4.38 (13% jump and a new 52 week high).


- Nov27th - TFST article released on SA at 2:35 pm - stock jumps again from below $4.20
to as high as $4.50 (breaking yet another 52 week high)


- Nov28th - Thanksgiving - market closed


- Nov29th - Friday - stock closes at $4.40
5/22/2018 The Big Picture At Unilife - Unilife Corporation (NASDAQ:UNIS) | Seeking Alpha


https://seekingalpha.com/article/1886091-the-big-picture-at-unilife 9/23


- Dec 2nd - Stock closes at $4.15 (down 6%) hitting a low of $4.03 again (right where it
began)


- Dec 2nd (after market close) - Novartis news released


The conclusion from this is that the stock had been quickly falling below $4.00 until it was
promoted by TFST and his distribution to his subscriber and then the follow through on
Seeking Alpha. The stock was quickly losing momentum again, and the only thing
resurrected it was a new press release regarding Novartis.


TFST is a paid stock recommendation letter. According to its results page, TFST has a
spectacular track record:


As our results show, The Focused Stock Trader recommendations were correct 52
out of 55 trades for an average return of 29.69% per trade with 2 trades generating
returns in excess of 200%. The average holding period for our recommended trades,
not including open trades, is 24 days. THE FOCUS STOCK TRADER HAS BEEN
CORRECT 95% OF THE TIME GENERATING 30% EVERY 24 DAYS.


A subscription to TFST costs $400 per quarter ($133 per month) or $1,200 per year ($100
per month) and the newsletter has over 100 subscribers.


A closer look at TFST reveals that many of these stock picks end up being for very
speculative reverse mergers which demonstrate great volatility. The research underlying
them is often questionable, yet TFST has apparently generated significant returns on the



http://www.thefocusedstocktrader.com/

http://www.thefocusedstocktrader.com/secured/members/blog/?page_id=333

http://www.thefocusedstocktrader.com/secured/members/blog/?page_id=333

https://static.seekingalpha.com/uploads/2013/12/8/4238561-13865531576032977-Richard-Pearson_origin.jpg
5/22/2018 The Big Picture At Unilife - Unilife Corporation (NASDAQ:UNIS) | Seeking Alpha


https://seekingalpha.com/article/1886091-the-big-picture-at-unilife 10/23


upside, quickly selling before these stocks fall back to Earth.


For example, back in August, TFST highlighted Organovo Holdings (NASDAQ:ONVO).
His track record notes that he had sold the stock for prices as high as $11.20. But when
the stock was trading at over $12.00, I highlighted the fact that much of its gains were due
to misinformation and inaccurate comparisons to 3D printing stocks such as 3D Systems
(NYSE:DDD) and Stratysys (NASDAQ:SSYS). The article from TFST contains the exact
type of misinformation that I had referred to. He noted that


Needless to say, Organovo can do for 3-D printing what Microsoft (NASDAQ:MSFT)
did for PCs and Ford (NYSE:F) did for the automobile; make a long-sought after
dream a reality.


Shortly after TFST was selling at $11.20, the stock quickly ended up falling below $8.00.
The stock has recently jumped due to the CEO's presentation at
retailinvestorconference.com. But even on that conference, the CEO went out of his way
to make clear that Organovo is NOT a 3D printing stock.


TFST clearly benefited from the rise in the Organovo even though its research was largely
unfounded. So, what's the harm?


The harm is that when uber bulls put out unfounded research on tiny, speculative reverse
mergers, investors end up buying into these stocks without understanding that there are
very substantial risks. TFST's next pick was Fab Universal (NYSEMKT:FU), which he
ended up making a whopping 99% on, selling it at $10.75. Congratulations to TFST,
however that stock has since been halted after a fraud expose by GeoInvesting. Prior to
the halt, this stock had last traded at $3.07. Trading has not yet resumed. Anyone who has
been stuck holding a Chinese microcap which has been halted due to fraud allegations
would likely not hold much optimism for the future of Fab. TFST was smart enough to get
out at $10.75, but its subscribers may not have been so lucky. On its website TFST notes
that:


In our reporting, we will suggest the purchase point; however, it is up to you to
decide when to close out the position.


Likewise, on Unilife, we will have no idea how quickly TFST will end up running for the
exits. In fact, it may well be the case that TFST will have the benefit of selling to
individuals who are still buying based on research provided by TFST.



https://seekingalpha.com/article/1628042-organovo-holdings-inc-revisited

https://seekingalpha.com/symbol/ONVO

http://www.thefocusedstocktrader.com/secured/members/blog/?page_id=333

https://seekingalpha.com/article/1848361-a-very-detailed-look-at-organovo

https://seekingalpha.com/symbol/DDD

https://seekingalpha.com/symbol/SSYS

https://seekingalpha.com/symbol/MSFT

https://seekingalpha.com/symbol/F

https://seekingalpha.com/symbol/FU
5/22/2018 The Big Picture At Unilife - Unilife Corporation (NASDAQ:UNIS) | Seeking Alpha


https://seekingalpha.com/article/1886091-the-big-picture-at-unilife 11/23


A longer look at the TFST track record shows a predisposition towards speculative and
volatile reverse merger stocks which often end up in the cross hairs of short sellers.
REVOLUTION LIGHTING (NASDAQ:RVLT) which TFST was selling as high as $5.00 was
later exposed by a short selling and fraud focused site the StreetSweeper. The stock
subsequently fell by as much as 50% from where TFST was selling, and it now sits at
around $2.80. But it appears to have been another great trade for TFST who got out early.
Likewise, it is very difficult to understand how anyone could have ever recommended
beleaguered OCZ Technology (NASDAQ:OCZ) which has been on terminal status for over
a year.


TFST had noted that :


Short sellers are still holding on, but perhaps not for long. OCZ's short position is at
an unsustainable 79.3%.


Within a month, the shares had already plunged by around 80%. Since that time the
shares have fallen by more than 95% and now trade for around 10 cents. It looks like
there was a reason why the short interest was so monumental.


Yet OCZ has continued to be a promo target even now. Ashraf Eassa recently warned that
there is still a campaign trying to spread rumor of a buyout on this now dead stock.


In separate disclosure on November 29th, TFST noted that his holding period was as
short as just 14 days. The point is that small reverse mergers can often pop due to the
sensation which surrounds vague press releases. This is especially true when the press
releases include the names of major, global industry players. As players such as TFST
have demonstrated, the best way to profit from such hype is to buy the rumor and (very
quickly) sell the news.


The supporters behind Unilife have demonstrated a consistent tendency to back
speculative, money losing reverse merger stocks. As with TFST, other backers have found
themselves on the opposite side from short sellers.


Tech Guru had previously penned an article to rebut the short thesis on Coronado
Biosciences (CNDO). Coronado had the implausible idea of making medical treatments
out of worm eggs which grow on pig feces. Tech Guru sought to debunk the short thesis
which had been highlighted again by such skeptics as the StreetSweeper.


In its "public oath" the StreetSweeper states that:



https://seekingalpha.com/author/the-focused-stock-trader/articles/symbol/rvlt

https://seekingalpha.com/symbol/RVLT

https://seekingalpha.com/article/822361-high-growth-ocz-technology-trading-in-the-discount-bin

https://seekingalpha.com/symbol/OCZ

https://seekingalpha.com/article/1868901-ocz-beware-the-message-board-pumpers

http://moxreports.com/wp-content/uploads/Our-Results-_-The-Focused-Stock-Trader.pdf

https://seekingalpha.com/article/1566582-coronado-separating-fact-from-fiction

http://www.thestreetsweeper.org/index.html
5/22/2018 The Big Picture At Unilife - Unilife Corporation (NASDAQ:UNIS) | Seeking Alpha


https://seekingalpha.com/article/1886091-the-big-picture-at-unilife 12/23


We aim to partner with the public in exposing corporate fraud and bringing its
engineers to justice. To that end, we pledge to investigate credible allegations of
misconduct and - if the evidence supports those accusations - report the truth about
our findings. At the same time, we agree to disclose any conflicts that could
potentially color our judgment. By embracing these core principles, we hope to
protect ordinary Americans and deliver them news that they can trust.


Readers can take that "public oath" with whatever grain of salt that they like. The point
from it is that sites such as the StreetSweeper do not focus on stocks which are merely
overvalued by 10-20% or which might have a bad earnings quarter. They are focused on
catalysts which are far more dramatic and which imply far larger share price moves.


As with Unilife, the shorts made their case by citing a horrible track record by
management, including huge share sales despite no revenues. In backing this company,
Tech Guru was defending the indefensible. As should have been expected, the use of
worm eggs from pig feces failed in clinical trials and the share price plunged from over
$8.00 to as low as $1.25. Yet the elevated share price before the failure allowed
management to raise over $200 million from stock sales over the past few years. The
shorts were particularly focused on the fact that a small group of insiders had been
repeatedly involved in similar speculative ventures which soared on the hype but which
imploded following large share sales. Since the implosion of Coronado, Tech Guru has
ceased providing further updates on the company.


The point from these examples is that generating excitement around tiny reverse mergers
which generate little to no revenue is far easier than generating excitement around larger
companies which are profitable and stable. This is precisely why promoters choose such
companies. Yet by ignoring or denying the warning signs highlighted by the skeptics, these
promoters can often encourage other investors to invest in stocks which have very
significant (and unknown) downside potential.


Other Unilife bulls appear to be engaged in a different strategy when writing about Unilife.


In the past year, Fusion Research has gone from zero articles on Seeking Alpha to almost
400. A new article appears from them on almost every trading day, with the result that
Fusion is now #1 on long ideas, #1 on services stocks and #1 on industrial goods. These
rankings are based purely on number of hits.


Fusion describes itself saying:



https://seekingalpha.com/article/1485231-unilife-is-2013-the-tipping-point-for-this-pharma-stock
5/22/2018 The Big Picture At Unilife - Unilife Corporation (NASDAQ:UNIS) | Seeking Alpha


https://seekingalpha.com/article/1886091-the-big-picture-at-unilife 13/23


Fusion Research is managed by a team that has been actively involved in the
financial research industry for over 5 years. Our business is rooted in principles of
trust, integrity and fundamentals-driven markets.


But it also notes that


We create strategic partnerships with companies and firms to gain
unprecedented domestic and international following of our coverage.


In fact, a closer look at Fusion's own website reveals that Fusion is actually an IT
outsourcing firm which focuses on simple web development and HTML. There is a link
where one can "learn more" about its investment research activities. But that link is broken
and leads to nowhere.


In its almost 400 articles, Fusion has consistently written about mega cap stocks which
have a huge built in following of thousands of readers. But it has also made it a point to
write about smaller stocks which have recently shown dramatic price moves and which will
also automatically generate a large number of hits.


The key point is as follows: During a two week period, shares of Unilife soared by as much
as 88% on the back of two press releases which are encouraging but still far too vague for
planning or forecasting purposes. Prior to this, the shares closed at $2.80 and the shares
have already begun a substantial retreat.


The attention of hyper bullish analysis can often have an even larger impact than the news
from the company itself. While this can often create great short term trading opportunities
for those who are nimble, holding these stocks after they peak can end up producing
substantial losses on the way down. Investors should be aware that those who promote
such stocks often have zero intention of holding the shares and often intend to play it as a
quick "buy on the rumor trade." Other authors are simply attracted to the most volatile
stocks which tend to generate the largest number of page views and typically do not even
buy the stocks they are writing about.


Section 3: Competitive considerations for Unilife


Many of the recent articles have been overwhelmingly focused on highlighting the
dramatic upside associated with Unilife while downplaying the substantial risks of buying
on this spike. They have also ignored the competition.



http://www.fusionoutsourcing.com/

http://www.fusionoutsourcing.com/
5/22/2018 The Big Picture At Unilife - Unilife Corporation (NASDAQ:UNIS) | Seeking Alpha


https://seekingalpha.com/article/1886091-the-big-picture-at-unilife 14/23


There is a reason why promotional authors tend to ignore the risks and competition: it
works.


We can very easily see what happens when an author pays even moderate attention to
risk elements after a stock has already spiked. Once the stock has spiked, any attention to
risk can send it sharply lower.


On December 2nd, Dr. Thomas Carr wrote a very bullish article on Unilife entitled "Unilife:
Set To Double In 2014?"" In his opening pitch, he notes that he is long the stock and that:


As it turns out, demand for Unilife's unique medical dispensing technology is so
strong and growing so fast that shares of the company may well be one of 2014's
best investments in the healthcare sector.


What was the result of this strong enthusiasm from one who identifies himself as a
"doctor?" The stock actually fell 7% that day. There are two reasons for this.


Despite his own personal bullishness and disclosing a long position in the stock, Dr. Carr
was forthright enough to at least mention the substantial downside that comes along with
Unilife. He noted that:


New and current investors should keep in mind the risks outlined above. The
company may well be covering up past fraudulent activity. The Biodel deal may well
fall through. Management may continue its unfortunate streak of over-selling its EPS
potential.


But of much greater importance was the fact that Dr. Carr was among the first to pay more
than passive lip service to the existence of substantial competition within this market.


Even Unilife itself discloses that there is meaningful competition in this space. But the
mostly retail investor base in Unilife often seems to feel that Unilife is inventing a new
product and will quickly command a monopoly in the space.


In its most recent 10K filing, Unilife discloses its view on the competition which already
consists of some of the largest and best financed giants in the healthcare industry, saying:



https://seekingalpha.com/article/1871871-unilife-set-to-double-in-2014
5/22/2018 The Big Picture At Unilife - Unilife Corporation (NASDAQ:UNIS) | Seeking Alpha


https://seekingalpha.com/article/1886091-the-big-picture-at-unilife 15/23


We are aware of five companies which specialize in the production and supply of
glass ready-to-fill syringes. These companies are BD, Gerresheimer, MGlas AG,
Schott and Nuova Ompi. We estimate the market concentration rate for these five
companies to be approximately 95%. We believe BD's market share to be in excess
of 50% as it has supply relationships with most pharmaceutical companies and
contract manufacturing organizations.


The point that investors need to realize is that this is not a soon-to-be-created new market
which will be dominated by Unilife. It is already an established and highly competitive
market.


In September, the big news for Unilife was the Sanofi contract which may eventually lead
to meaningful sales of Lovenox in prefilled syringes. But in its September conference call,
Unilife noted that


the IMS data for Lovenox for 2012 shows the sale of over 450 million prefilled
syringes with Lovenox in it.


The point is that there are already hundreds of millions of units of being provided by
competitors on the market two years before Unilife even plans on entering the picture in
2014. Many investors have been entirely unaware of this competitive reality and have
assumed that Unilife is about to create a multi billion dollar monopoly.


Dr. Carr briefly listed a number of Unilife's competitors within the space who have existing
or pending product offerings which will largely compete within the same space.


In addition to Beckton Dickinson (BD), Gerresheimer, MGlas AG, Schott and Nuova Ompi
(which were mentioned by Unilife), Dr. Carr also mentions such giants as Amgen
(NASDAQ:AMGN), Pfizer (NYSE:PFE) and West Pharmaceuticals (NYSE:WST). Medical
giant Baxter International (NYSE:BAX) is also active in prefilled syrniges. Baxter is valued
at $37 billion based on annual sales of over $14 billion.


The point is that breaking into this space will be difficult, even despite several encouraging
potential supply contracts. The competition in this space is well established and extremely
well financed and will have the ability to compete aggressively on volume, quality and
price.


Conclusion



http://www.secinfo.com/%24/SEC/Documents.asp?CIK=1476170&Type=EX-10

https://seekingalpha.com/article/1685592-unilife-management-discusses-q4-2013-results-earnings-call-transcript

https://seekingalpha.com/symbol/AMGN

https://seekingalpha.com/symbol/PFE

https://seekingalpha.com/symbol/WST

https://seekingalpha.com/symbol/BAX
5/22/2018 The Big Picture At Unilife - Unilife Corporation (NASDAQ:UNIS) | Seeking Alpha


https://seekingalpha.com/article/1886091-the-big-picture-at-unilife 16/23


The market has now had the opportunity to digest in full the recent news from Unilife along
with the ample analysis from third party authors. CEO Alan Shortall has had the
opportunity to speak to investors in New York and the sell side analysts have already had
their chance to upgrade the stock.


With all of these events now being mostly digested, the stock appears to be once again
giving up its recent gains rather than continuing to surge higher.


The market may well be already pricing in an equity offering due to the realization that
Unilife will likely be out of cash before Christmas.


Much of the sharp rises in the stock can be tied to recent promotional articles by authors
who tend to focus on short-term trades in speculative reverse merger stocks. In the past,
some of these efforts have sensationalized press releases from other micro cap reverse
mergers and have predicted a surge in near-term revenues and multi bagger share price
returns. This is an easy task when the press release includes the names of global giant
heavy weights.


But when similar such press releases have been consistently issued for years without
meaningful resulting revenues, investors should likely ask themselves how the latest
series of press releases will create a result that is in any way different.


There is already existing competition in the specialty syringe space with hundreds of
millions of units being delivered even just for individual drugs such as Lovenox. Those
who have been under the impression that Unilife has created a novel product and will
soon be commanding a monopoly would do well to expand their research into the
substantial competition in the specialty syringe space.


Appendix I - details of Unilife lawsuit


For those who wish to read the details of the Unilife lawsuit in its entirety, updating filings
from August can be found at the following link at my website at moxreports.com. Readers
can also sign up for email alerts. There is no charge for this and email addresses are not
shared with anyone. Ever.


Readers should also be aware that Unilife has already responded to the article on Forbes.
A link to that response can be found here. However, readers should also note that there
are a number of items in the actual whistle blower lawsuit which do not yet appear to have
been responded to by management.



http://moxreports.com/wp-content/uploads/UNIS-whistleblower-lawsuit.pdf

http://www.secinfo.com/d14D5a.xB1pz.d.htm?Find=forbes&Line=37
5/22/2018 The Big Picture At Unilife - Unilife Corporation (NASDAQ:UNIS) | Seeking Alpha


https://seekingalpha.com/article/1886091-the-big-picture-at-unilife 17/23


The lawsuit was brought by Talbot Smith, formerly an executive at Unilife who was hired in
2011. The suit notes that Smith was a Stanford graduate with a BS in Industrial
Engineering and an MS in Operations Research. His starting salary was $230,000 plus
various incentives including bonuses and stock options.


The gist of this lawsuit can be seen on the first page of the filing. The cited "causes of
action" are a) violations of Sarbanes Oxley and b) violations of the Dodd-Frank Act.


Sarbanes Oxley (or "SOX") was passed in 2002 in direct response to various accounting
scandals including Enron, Tyco and Worldcom. SOX requires that top management certify
the accuracy of SEC filings and dramatically increased the penalties for fraudulent activity.


Dodd Frank was passed into Federal Law in 2010 in response to the financial crisis which
began in 2008 and also was designed to incorporate enhanced protections for investors.


As noted, the lawsuit was originally filed and received by the US Department of
Labor/OSHA. The lawsuit notes that the Secretary of Labor did not make a final
determination within the 180 day deadline, but that "sufficient prima facie evidence was
found to begin an investigation" (page 2). As a result, the case was moved to Federal
Court.


This filing is very long because it also incorporates original copies of the press releases
and the 10K filing which are said to contain the inaccurate statements.


Some of the claims by Smith state that products being supplied by Unilife were not
"validated" (as had been claimed by Unilife) because the FDA required activities had not
been completed at the time that these statements were made to investors. Unilife
subsequently brought in FDA auditors who stated that by the time of the audit, the
validation could be considered complete.


These FDA claims will therefore be very difficult for either side to verify. The argument
Talbot would make is that compliance would have been achieved well after he reported his
observations to the FDA, but prior to the audit. The argument from Unilife is simply that
this is not true.


Other claims should be less ambiguous. For example, on page 7, we can see Smith's
claim that the previous 10K filing made inaccurate statements to investors regarding
shipments of "commercial" product by Unilife. Talbot backs this statement by noting that
"no revenue had been collected from commercial sales of the Unifill product." Ultimately,
an audit by the SEC will be able to trace documentation of this claim and make a
determination. This should be black and white.
5/22/2018 The Big Picture At Unilife - Unilife Corporation (NASDAQ:UNIS) | Seeking Alpha


https://seekingalpha.com/article/1886091-the-big-picture-at-unilife 18/23


Likewise, Talbot claims Unilife made false statements about its production lines. Talbot
claims that at the time of the statements, two of the production lines were actually still in
Denver, Colorado, and certainly not installed. Again, this should be a very black and white
matter to resolve in an investigation.


In general, I am far less focused on the FDA issues because I believe that they will be far
more difficult for either side to resolve. But on Page 11, the lawsuit describes additional
product quality failures which had supposedly been reported by Smith via email. The
lawsuit then notes that


The following day, Mojdeh told Smith to come into his office. Mojdeh instructed Smith
that he should not put any concerns into emails because they could be used against
the company in future legal action


Once again, an investigation will certainly dig up any emails prior to this conversation.
Either the emails referred to by Smith exist or they do not, so there should be a conclusive
result to an investigation by the SEC.


Other claims may be easy to document, even though actual "intent" may be hard to prove.
On page 11, the lawsuit notes that:


Unilife also took actions to mislead investors about its customer demand and
manufacturing capacity. To this end, Mojdeh directed Smith to have his team
purchase 1,000,000 units of Unifill components per month in spite of the fact that
there was no customer demand or manufacturing capacity to justify this level of
purchasing. Mojdeh told Smith that the objective of the purchases was to make
suppliers believe that Unilife was manufacturing at this volume, with the hope that
the information would leak to the financial markets.


The point here is that proving that Unilife made unnecessary purchases at huge volume
should be relatively straight forward. And this could easily be explained by the ballooning
losses and dwindling revenues seen over the past 3 years. Yet actually proving the intent
of Mr. Mojdeh will likely be a more difficult endeavor in an investigation or a courtroom.


On page 12, the lawsuit states that:
5/22/2018 The Big Picture At Unilife - Unilife Corporation (NASDAQ:UNIS) | Seeking Alpha


https://seekingalpha.com/article/1886091-the-big-picture-at-unilife 19/23


Another action that Unilife took to mislead investors was to run fake production when
investors or customers were visiting the facility. On more than one occasion, scrap
was run through the machines to make it appear that Unilife was making product
when it was not. Product was placed on skids by the warehouse doors to give the
false appearance that product was being packaged and send to customers when it
was not.


Presumably the only way to get much resolution will be when the SEC subpoenas the
warehouse workers who either did or did not perform these activities. The truth should be
easy to get at because warehouse workers typically do not have a large financial inventive
to bend the truth when faced with the potential for perjury charges. In addition, there are
likely a large number of warehouse workers. Keeping a secret gets harder as the number
of individuals increases.


On Page 13, the lawsuit notes that


Shortall made comments that were posted on the Yahoo Finance message board on
July 10th, 2012, indicating that Unitract was profitable with a 20% gross margin,
when Unilife was in fact losing $1.00 per unit.


Again, this will be an easy one to either prove or disprove.


Conclusions regarding Unilife lawsuit


The details spelled out in the lawsuit vary between crystal clear and verifiable to murky
and difficult-to-prove. Some investors may be inclined to wonder why we have not already
seen some resolution to these matters given that they relate to issues dating back to 2011.
Other investors may be inclined to feel that if we haven't seen consequences yet, then
there may simply be nothing to worry about.


In general, SEC investigations take considerable time and there are no "hints" along the
way which would give guidance as to the eventual conclusion. For example, in October
2013 the SEC was just providing final resolution to the fraud case at YuHe International,
which has been ongoing since 2011. China frauds were a big focus in 2011, and in
October 2013 the SEC finally got around to issuing final judgment against China Media
Express ("CCME"), also following fraud that was uncovered in 2011. The point is that
these things can often take a few years before visible results are uncovered. No one
should expect that there would have already been an immediate result just because these
findings were made public over a year ago.



http://www.sec.gov/litigation/litreleases/2013/lr22833.htm
5/22/2018 The Big Picture At Unilife - Unilife Corporation (NASDAQ:UNIS) | Seeking Alpha


https://seekingalpha.com/article/1886091-the-big-picture-at-unilife 20/23


Comments (18)


Disclosure: I am short UNIS, ONVO. I wrote this article myself, and it expresses my own
opinions. I am not receiving compensation for it. I have no business relationship with any
company whose stock is mentioned in this article.


Additional disclosure: The author was previously an investment banker for a major
global investment bank and was engaged in investment banking transactions with a wide
range of healthcare companies including medical device, pharmaceutical, genomics and
biotech companies. The author has not been engaged in any investment banking
transactions with US listed companies during the past 5 years. The author is not a
registered financial advisor and does not purport to provide investment advice regarding
decisions to buy, sell or hold any security. The author currently holds a short position in the
stock of UNIS and has provided fundamental and technical research to investors who hold
a short position in the stock. The author may choose to transact in securities of one or
more companies mentioned within this article within the next 72 hours. Before making any
decision to buy, sell or hold any security mentioned in this article, investors should consult
with their financial adviser. The author has relied upon publicly available information
gathered from sources which are believed to be reliable and has included links to various
sources of information within this article. However, while the author believes these sources
to be reliable, the author provides no guarantee either expressly or implied.


 Like this article


atrickpay
liking this analysis on TFST. author, how the heck do you know they only have 100 subscribers tho?


09 Dec 2013, 12:18 PM


atrickpay
author: why do you say novartis news came out 11/1911.20? it came out via p/r anyways on 12.02. Here's the link to
their official press releases: http://bit.ly/1iQ7fXi


09 Dec 2013, 12:36 PM


Unifollower
Just love you shorters sweat. 
You haven't done your homework. 
The fact is that, at the request of Pharma's, UNIS have invented a whole suite of unique devices needed by them so
that they can get their modern drugs to market. 



https://seekingalpha.com/symbol/UNIS

https://seekingalpha.com/symbol/ONVO

https://seekingalpha.com/user/710490

https://seekingalpha.com/user/710490

http://bit.ly/1iQ7fXi

https://seekingalpha.com/user/1385141
5/22/2018 The Big Picture At Unilife - Unilife Corporation (NASDAQ:UNIS) | Seeking Alpha


https://seekingalpha.com/article/1886091-the-big-picture-at-unilife 21/23


Development money is flowing in and will show up in this quarter financials. 
If UNIS needs money they have shareholders permission to raise it, and you will only know about after its done. 
Go to UNIS website and see the beautiful products that have no equal. 
Do you really think that the huge global Pharma's that have contracted with UNIS are stupid and haven't tried to
source UNIS products from the likes of BDX. 
They have, only to find that they are not available, and so they went to UNIS to invent exactly their needs.


09 Dec 2013, 02:15 PM


sooker
The $64,000 question is, how many more deals will it take before the shorts become believers?


09 Dec 2013, 02:17 PM


silence_twain
When they actually start delivering the product in quantity to people, that is when shorts will begin to believe
the story. UNXL signed lots of deals too. How much of their product is rolling off the assembly line today?


10 Dec 2013, 10:27 AM


sooker
Can someone please explain why some of the contracts signed to date involve upfront and milestone payments made
by Pharma?


Why do Pharma need to pay upfronts when Unilife offer products that are supposedly available elsewhere?


09 Dec 2013, 02:31 PM


califmla
Dam! UNIS must have stepped on your toes. I hope not too many people read your article because I do have a
sizable stake in UNIS. As I understand it, Obamacare with the state wide and the national US citizen Immunization
program starting in 2014 will be a great opportunity for companies like UNIS. Correct me if I'm wrong.


09 Dec 2013, 05:16 PM


bbq13
Ok your short We get it. Too many people have caught on to the UNIS upside so please cover your Short and move
on.


09 Dec 2013, 06:05 PM


Tshar
Hmmm. I wonder why the stock is not budging?


09 Dec 2013, 08:17 PM



https://seekingalpha.com/user/1117319

https://seekingalpha.com/user/954931

https://seekingalpha.com/user/1117319

https://seekingalpha.com/user/19269561

https://seekingalpha.com/user/19399881

https://seekingalpha.com/user/11200911

https://seekingalpha.com/user/3084411
5/22/2018 The Big Picture At Unilife - Unilife Corporation (NASDAQ:UNIS) | Seeking Alpha


https://seekingalpha.com/article/1886091-the-big-picture-at-unilife 22/23


bronx54
It's really good to read some honest opinions for a change. All the longs want to hear is everything is going great. I
was long this stock, but after doing some real due diligence sold out. I have been around the track to long to smell a
rat. The management of this company has a very bad track record. I to believed I had found a real winner, boy was I
wrong.


09 Dec 2013, 08:27 PM


califmla
to bronx54 
From one old timer to another I would be pleased for you to reference your REAL due diligence. Believe me,
I'm not trying to be derogatory in any way. I am a straight up man and would say the same to my best friend.
I'm just asking for some of your insources of D.D., which seems to be better than mine. In other words as they
say "Put your money where your mouth is." :) I have been humbled before and it's OK. That's the way you
learn. Ã´Â¿Ã´


10 Dec 2013, 08:49 PM


leonct74
Once again, Mr Pearson is a declared short on ONVO and UNIS. Just in case you missed his disclosure.


The factual difference between TFST reports and Mr Pearson articles is that investors who have followed TFST have
probably made some money investing in ONVO and those who have followed Mr Pearson advice would have lost a
good opportunity. Just look at ONVO YTD trading.


ONVO is considered a 3d printing stock even by Nomura, read the yesterday article about Nomura's James Kim
comments: http://bit.ly/1cynxyI 
I think they are a pretty reliable source of information than an individual investors without any trackable experienceâ¦ 
Big companies who are in collaboration with ONVO are quite reliable as well... just to make a couple of names: Pfizer,
Roche, Autodesk


Mr Pearson's last article about ONVO was a good example how carefully need to be read his articles He had
developed an entire bearish article around the news of ONVO 4M shares dilution without even mentioning the most
important part: ''THE PURPOSE'' of the dilution!!


I'm long in ONVO and advise anyone to use his own diligence.


10 Dec 2013, 08:34 AM


Thomas Carr, Contributor
Hi David, Thanks for your balanced critique of my UNIS article and for the very thorough analysis of the company and
industry. For the record, I am currently out of UNIS, having banked a nice gain. I'm a trader mostly, and only rarely a
long-term holder. As for the "doctor" part, that's a product of nearly 10 years of largely misdirected education at
Oxford! (lovely place, though). Blessings and happy trading, TC


10 Dec 2013, 11:00 AM



https://seekingalpha.com/user/3084411

https://seekingalpha.com/user/19269561

https://seekingalpha.com/user/17812342

http://bit.ly/1cynxyI

https://seekingalpha.com/author/thomas-carr
5/22/2018 The Big Picture At Unilife - Unilife Corporation (NASDAQ:UNIS) | Seeking Alpha


https://seekingalpha.com/article/1886091-the-big-picture-at-unilife 23/23


suhaas
Who is David?


Anyway, you wrote on Dec 2nd about how great this company is and you already sold, 5 days later?


11 Dec 2013, 01:52 PM


Thomas Carr, Contributor
Hi Suhaas. Sorry, I meant Richard (the author); apologies. As for UNIS, I'm a trader-investor. I follow story
stocks with improving fundamentals and buy on base breakouts, sell on distribution...again and again until the
trend has run its course. I really like the UNIS story but also recognized the risks in my article. I'll be back in
again soon, no doubt. Hope that helps explain! Blessings, TC


11 Dec 2013, 03:21 PM


walterthestorm
There are three big differences from the past. Firstly, the CEO has surrounded himself with many ex Becton
Dickenson employees. These guys know needles. Secondly, these are deals with major Pharma companies:
AstraZeneca, Novartis, sanofi etc... and thirdly, their product offerings are much more diverse than 9 years ago. I
admit the CEO is a little too much of a cheerleader but if these pharma companies keep signing up to use their
products the upside could be huge.


10 Dec 2013, 08:31 PM


suhaas
Watch out! Anyone who says anything even remotely adverse to this writer, will get a " respectful" letter from Alpha,
saying they deleted your comment. Well, this comment does not have a long life too. They will " respectfully" delete
this, claiming I have made a blanket statement disagreeing with the author, which I have not! ( Not in this comment,
anyway, nor in several other comments, that they deleted, just because it contained criticism of Alpha)


I guess they are not smart enough to understand that one sided commentary, will be the death knell of their site.


11 Dec 2013, 01:29 PM


Restino
It seems based on the chart that the shorters are losing their battle. This leads me to believe that the market is finally
understanding the contracts value and the product differentiation.


I am long and have been since the last time I shorted. I make money understanding the value of the perception of the
company/stock as seen by the market.


And I see the market telling me to stay long.


12 Dec 2013, 09:06 AM



https://seekingalpha.com/user/110699

https://seekingalpha.com/author/thomas-carr

https://seekingalpha.com/user/740271

https://seekingalpha.com/user/110699

https://seekingalpha.com/user/7837211
